Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer Patients with MCRC were randomly ...
Patterns of care for patients with non-metastatic castration-resistant prostate cancer: Population-based study in Ontario, Canada. This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary ...
Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human ...
Gemstone-301: A phase III clinical trial of CS1001 as consolidation therapy in subjects with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who have not progressed after ...
*Safety data percentages are calculated from the safety population (n=338 for durvalumab + GemCis and n=342 for placebo + GemCis). This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal ...
Over the past decade, significant advances have been achieved in the diagnostic testing, treatment, and prognosis of advanced non–small-cell lung cancer (NSCLC). One of the most significant ...
Efforts to reduce global cancer disparities begin with an understanding of geographic patterns in cancer incidence, mortality, and prevalence. Using the GLOBOCAN (2002) and Cancer Incidence in Five ...
Improving detection of higher-risk or locally advanced disease features in stage I and II renal cell carcinoma. This is an ASCO Meeting Abstract from the 2020 Genitourinary Cancers Symposium. This ...
The decision to treat a patient with stage II colon cancer with adjuvant chemotherapy can be challenging. Although the benefit of treatment is clear in most patients with stage III disease, the ...
Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject ...
This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.
Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer The following represents disclosure information ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results